Celldex Therapeutics Company
Celldex is developing monoclonal and bispecific antibodies that address devastating diseases for which available treatments are inadequate.
Technology:
Neurological Disorders
Industry:
Genomic and Epigenominc Instabillity
Headquarters:
United States
Founded Date:
1983
Employees Number:
101-250
Funding Status:
IPO
Estimated Revenue:
Less than $1M
Register and Claim Ownership